High induction dosing of risankizumab in patients with moderate-to-severe plaque psoriasis: Interim results from the phase 2 KNOCKOUT study

被引：0

作者：

Blauvelt, A. ^{[1
]}

Gudjonsson, J. ^{[2
]}

Matheson, R. ^{[1
]}

Liu, R. ^{[3
]}

Shi, L. ^{[3
]}

Photowala, H. ^{[3
]}

Ehst, B. ^{[1
]}

机构：

[1] Oregon Med Res Ctr, Portland, OR USA

[2] Univ Michigan, Dept Dermatol, Sch Med, Ann Arbor, MI USA

[3] AbbVie Inc, N Chicago, IL USA

来源：

JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2023年 / 143卷 / 09期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

LB1703

引用

页码：B16 / B16

页数：1

共 50 条

[21] Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis
Gordon, K. B.
Lebwohl, M.
Papp, K. A.
Bachelez, H.
Wu, J. J.
Langley, R. G.
Blauvelt, A.
Kaplan, B.
Shah, M.
Zhao, Y.
Sinvhal, R.
Reich, K.
BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (03) : 466 - 475
[22] RNA-seq genomic analysis demonstrated the molecular efficacy of Risankizumab in a moderate-to-severe plaque psoriasis phase 2 clinical study
Pakozdi, T.
Georgantas, R.
Grebe, K.
Davis, W.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (05) : S59 - S59
[23] RNA-seq genomic analysis demonstrated the molecular efficacy of risankizumab in a moderate-to-severe plaque psoriasis phase 2 clinical study
Pakozdi, T.
Georgantas, R. W.
Grebe, K. M.
Visvanathan, S.
Baum, P.
Davis, W.
EXPERIMENTAL DERMATOLOGY, 2018, 27 : 21 - 21
[24] Disease severity in moderate-to-severe plaque psoriasis: Results from the Belgian REDISCOVER study
Hillary, Tom
Ghys, Liesbeth F. E.
Willaert, Fabienne
Swimberghe, Sandra
Lecuyer, Myriam
Ghislain, Pierre-Dominique
Morrens, Joachim
Lambert, Jo L. W.
JEADV CLINICAL PRACTICE, 2024, 3 (05): : 1487 - 1498
[25] Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
Armstrong, April W.
Soliman, Ahmed M.
Gisondi, Paolo
Fang, Siran
Patel, Manish
Strober, Bruce
DERMATOLOGY AND THERAPY, 2024, 14 (11) : 3071 - 3081
[26] Disease severity in moderate-to-severe plaque psoriasis: results from the Belgian REDISCOVER study
Hillary, Tom
Ghys, Liesbeth
Willaert, Fabienne
Swimberghe, Sandra
Lecuyer, Myriam
Ghislain, Pierre-Dominique
Morrens, Joachim
Lambert, Jo
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB37 - AB37
[27] Real world experience of brodalumab treatment in patients with moderate-to-severe plaque psoriasis in the Greek population: Results from an interim analysis of the BrIDGE study
Rigopoulos, Dimitrios
Angelakopoulos, Charalampos
Apalla, Zoi
Georgiou, Sophia
Delli, Florentina
Drosos, Alexandros
Zafiriou, Efterpi
Katsantonis, John
Lazaridou, Elisavet
Panagakis, Pantelis
Papadavid, Evangelia
Papakonstantis, Markos
Roussaki-Schulze, Angeliki-Viktoria
Sotiriou, Elena
Anastasiadis, Georgios
Tampouratzi, Eleftheria
Chasapi, Vasiliki
Sfaelos, Konstantinos
Ioannides, Dimitrios
DERMATOLOGIC THERAPY, 2022, 35 (12)
[28] Risankizumab Efficacy for Moderate-to-Severe Plaque Psoriasis over 256 Weeks in Patients with Prior Biologic Treatments
Crowley, Jeffrey
Hong, Chih-Ho
Gooderham, Melinda
Kokolakis, Georgios
Photowala, Huzefa
Rubant, Simone
Zhan, Tianyu
Blauvelt, Andrew
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB82 - AB82
[29] Efficacy of switching from ustekinumab to guselkumab in patients with moderate-to-severe plaque psoriasis: Results from the NAVIGATE study
Langley, Richard G.
Tsai, Tsen-Fang
Flavin, Susan
Song, Michael
Randazzo, Bruce
Wasfi, Yasmine
Li, Shu
Puig, Luis
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB120 - AB120
[30] Risankizumab in obese patients with moderate-to-severe plaque psoriasis: a 104-week, real-world, retrospective study
Rompoti, Natalia
Koumprentziotis, Ioannis-Alexios
Stefanaki, Irene
Vavouli, Charitomeni
Papoutsaki, Marina
Politou, Maria
Panagakis, Pantelis
Befon, Angeliki
Kousta, Fiori
Lazou, Eleni
Chasapi, Vasiliki
Stratigos, Alexander
Nicolaidou, Electra
ARCHIVES OF DERMATOLOGICAL RESEARCH, 2024, 316 (09)

← 1 2 3 4 5 →